VN February 2021

Vetnews | February 2021 7 Some clinical studies showed no benefits or worsening of disease after ivermectin use, 11-14 whereas others reported shorter time to resolution of disease manifestations attributed to COVID-19, 15-18 greater reduction in inflammatory markers, 16,17 shorter time to viral clearance, 11,16 or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo. 11,16,18 However, most of the studies reported to date had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. The missing information and limitations include the following: • The sample size of most of the trials was small. • Various doses and schedules of ivermectin were used. • Some of the randomised controlled trials were open- label studies in which neither the participants nor the investigators were blinded to the treatment arms. • In addition to ivermectin or the comparator drug, patients also received various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids), confounding assessment of the true efficacy or safety of ivermectin. • The severity of COVID-19 in the study participants was not always well described. • The study outcome measures were not always clearly defined. Because of these limitations, the Panel cannot draw definitive conclusions about the clinical efficacy or safety of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well- conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19. References available on request as well as on the website from which the guidelines were sourced (see above) The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives. v Check out our amazing offer on the Vivix 1717 and 1417 flat panel digital detectors. Trade-in your existing CR unit and get than previously offered! Don't have a CR unit to trade-in? We will give you an additional off the quoted price! Don't miss out on this special discount! Call us today for an obligation free demo at your practice. www.lomaenmedical.co.za OFFER VALID UNITL THE END OF FEBRUARY 2021 | TERMS AND CONDITIONS APPLY R20k more 5% discount Leading Article

RkJQdWJsaXNoZXIy OTc5MDU=